DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Maprotiline (Maprotiline Hydrochloride) - Summary

 
 



Suicidality and Antidepressant Drugs

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of maprotiline or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Maprotiline is not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening and Suicide Risk, PRECAUTIONS: Information for Patients and PRECAUTIONS: Pediatric Use.)

 

MAPROTILINE SUMMARY

MAPROTILINE HYDROCHLORIDE TABLETS, USP

Maprotiline hydrochloride, USP is a tetracyclic antidepressant, available as 25 mg, 50 mg and 75 mg tablets for oral administration.

Maprotiline hydrochloride tablets are indicated for the treatment of depressive illness in patients with depressive neurosis (dysthymic disorder) and manic-depressive illness, depressed type (major depressive disorder). Maprotiline is also effective for the relief of anxiety associated with depression.


See all Maprotiline indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Maprotiline

USPSTF Recommends Depression Screening for Older Adolescents
Source: Medscape Pediatrics Headlines [2016.02.09]
Adolescents aged 12 to 18 years should be screened for major depressive disorder when adequate care systems are in place, according to the USPSTF.
Medscape Medical News

ACP: CBT and antidepressants are similarly effective treatments for adults with depression
Source: Depression News From Medical News Today [2016.02.09]
Doctors should discuss treatment effects, adverse effect profiles, costs, accessibility, and preferences with patients when selecting a first line treatment.

CBT and antidepressants 'equally effective' for major depression
Source: Depression News From Medical News Today [2016.02.09]
The ACP compared the effectiveness cognitive behavioral therapy and antidepressants for major depression, finding that the two treatments are just as beneficial.

USPSTF Backs Screening Teens for Major Depression (CME/CE)
Source: MedPage Today Psychiatry [2016.02.09]
(MedPage Today) -- Group takes no position on screening younger kids

Poor REM Sleep May Be Linked to Higher Risk for Anxiety, Depression
Source: MedicineNet Depression Specialty [2016.02.09]
Title: Poor REM Sleep May Be Linked to Higher Risk for Anxiety, Depression
Category: Health News
Created: 2/8/2016 12:00:00 AM
Last Editorial Review: 2/9/2016 12:00:00 AM

more news >>

Published Studies Related to Maprotiline

Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males. [2007.11]
BACKGROUND: To investigate the effects of antidepressants on glucose-insulin homeostasis, we provided homogenous situation and performed standard procedures to assess the interactions of antidepressants and glucose regulation during hospitalization... CONCLUSIONS: The results suggest that the beta-cell function is hyperbolic in order to offset the insulin resistance following maprotiline treatment. Our findings imply that norepinephrine reuptake inhibitor (NRI) antidepressants might attenuate insulin sensitivity.

more studies >>

Clinical Trials Related to Maprotiline

Pharmacovigilance in Gerontopsychiatric Patients [Recruiting]
The purpose of this multicenter-study is to investigate safety of psychopharmacological treatment and rates of adverse drug reactions in gerontopsychiatric inpatients. Elderly people are at higher risk for developing side effects under pharmacological treatment due to an altered metabolic situation, higher comorbidity rates and often polypharmacy. Furthermore gerontopsychiatric patients can often not articulate their symptoms clearly, for example due to pronounced cognitive impairment. The aim of the study is to gain valid data of possible adverse drug reaction rates, their potential risk factors and outcome, as well as medical prescription practises. To assess these outcomes an intensive pharmacovigilance-monitoring will be conducted at the five participating study sites. At Baseline demographic data, previous and present disorders, use of drugs, previous and present medication, quality of life, cognitive function, physical examination results, laboratory results and ECG will be assessed. Afterwards patients are visited weekly and screened for possible adverse drug reactions. All adverse drug reactions will be coded in the MedDRA-system. In case of a possible serious adverse drug reaction serum levels of all psychotropic substances applicated will be assessed. Drug combinations will be analysed using an established advanced bioinformatic tool (mediQ). Diagnosis, medication intake and possible adverse drug reactions are documented continually. 2 weeks after discharge from the ward, patients will be contacted by phone to assess catamnestic data.

Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism [Completed]
Reduction of volume of the hippocampus has been associated with major depression in many studies. It has been suggested that antidepressants may protect against hippocampus volume loss in humans associated with multiple episodes of depression and may also reverse the reduction of volume caused by the depression. In addition, genetic markers for serotonin are implicated with depression, and may be an indication of reduced response to antidepressant treatments. This study aims to enroll patients who are defined as having treatment resistant depression (no remission after at least 2 treatments trials with an antidepressant). They will receive an MRI scan at the initial visit and either 6 months after sustained remission or 12 months after they enter the study for non-remitters. They will also be asked to give a blood sample for genotyping. They will be matched by age and handedness to healthy volunteers with no personal history of depression who will also receive an MRI scan and genotyping. The first aim is to compare hippocampal volume of depressed subjects to healthy controls. It is anticipated that subjects will initially have smaller hippocampal volume but of those who sustain remission, there will be a small increase in hippocampal volume. It is also anticipated that specific genetic markers will be related to individuals response to antidepressant treatments.

more trials >>


Page last updated: 2016-02-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015